Description
Product Usage Information
Western Blotting: 1:1000
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.
Protocol
Available protocols: Western Blotting
Specificity / Sensitivity
LIF (F6X1X) Rabbit Monoclonal Antibody recognizes endogenous levels of total LIF protein.
Species Reactivity: Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to human LIF protein.
Background
Leukemia inhibitory factor (LIF) is a pleiotropic member of the interleukin-6 (IL-6) family of cytokines (1). LIF binds the dimeric receptor LIFRα/gp130 to form a functional trimer (2). The trimeric LIF/LIFR/gp130 complex further interacts with JAK1, making it catalytically competent. The activated JAK1 then initiates a tyrosine phosphorylation cascade that stimulates three distinct signaling pathways: JAK/STAT, MAPK, and PI3K pathways (3). During development, LIF plays important roles in embryonic stem cell pluripotency, blastocyst implantation, and early neural development. It is also crucial for intestinal stem cell and neuronal stem cell self-renewal and regeneration, muscle and kidney tissue regeneration after injury, and immune tolerance (4). LIF's regulatory role in cancer is context-dependent. It plays a tumor suppressive role in leukemia, but is overexpressed and exerts an oncogenic effect in solid tumors (4,5). Targeting LIF for cancer therapy is promising for disease management (6,7).
Alternate Names
CDF; cholinergic differentiation factor; D factor; DIA; differentiation inhibitory activity; differentiation stimulating factor; differentiation-inducing factor; Differentiation-stimulating factor; hepatocyte-stimulating factor III; HILDA; human interleukin in DA cells; Leukemia inhibitory factor; leukemia inhibitory factor (cholinergic differentiation factor); LIF; LIF interleukin 6 family cytokine; Melanoma-derived LPL inhibitor; MLPLI
